PureTech Health

PureTech Health is a biotechnology company which develops medicines to combat serious diseases. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.

PureTech Health
TypePublic
IndustryHealthcare
Founded2005
HeadquartersBoston, United States
Key people
Christopher Viehbacher (Chairman)
Daphne Zohar (CEO)
ProductsMedicines
RevenueDecrease $15.6 million (2022)[1]
Decrease $(197.8) million (2022)[1]
Increase $(37.4) million (2022)[1]
Websitepuretechhealth.com

History

The company was founded by Daphne Zohar, an American entrepreneur, in 2005.[2] It was the subject of an initial public offering on the London Stock Exchange in June 2015.[3]

Operations

Companies which PureTech Health founded include Karuna Pharmaceuticals,[4] Gelesis, which has received FDA approval as a treatment for weight management,[5] Akili Interactive Labs, which is developing a digital therapeutic platform for cognitive disorders,[6] Vedanta Biosciences, which is developing drugs to treat autoimmune and inflammatory diseases,[7] and Follica which is developing new treatments for androgentic alopecia among others.[8] PureTech also has a pipeline of its own immunology, lymphatic and oncology based therapeutics.[9]

References
  1. "Annual Results 2022". PureTech Health. Archived from the original on 28 April 2023. Retrieved 28 April 2023.
  2. "PureTech's long view on biopharma". Boston Globe. 26 August 2015. Archived from the original on 16 August 2019. Retrieved 16 August 2019.
  3. "PureTech banks $171M in a London IPO to fund its biotech bets". Fierce Biotech. 19 June 2015. Archived from the original on 16 August 2019. Retrieved 16 August 2019.
  4. "PureTech Health surges as Karuna investment rockets 442%". Proactive Investors. 19 November 2019. Archived from the original on 14 December 2019. Retrieved 14 December 2019.
  5. "Gelesis raises $12 million for pill that staves off hunger". BetaBoston.com. May 16, 2014. Archived from the original on August 3, 2014. Retrieved December 14, 2019.
  6. "Akili Interactive adds $13 million to Series C funding pool". The Pharma Letter. 9 August 2018. Archived from the original on 14 December 2019. Retrieved 14 December 2019.
  7. "PureTech Health affiliate Vedanta Biosciences awarded $5.8m grant". Sharecast. 5 December 2019. Archived from the original on 14 December 2019. Retrieved 14 December 2019.
  8. "Positive Results From PureTech Affiliate Male Pattern Hair Loss Study". Morning Star. 13 June 2019. Archived from the original on 1 March 2020. Retrieved 14 December 2019.
  9. "PureTech Licenses Glyph Lymphatic Technology". FT. 29 August 2017. Archived from the original on 15 January 2020. Retrieved 14 December 2019.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.